checkAd
    Startseite > Aktien > ChromaDex > Nachrichten
    ChromaDex Aktie
    3,7800
     
    USD
    +0,53 %
    +0,0200 USD
    Letzter Kurs 04.05.24 Nasdaq
    3,7600
     
    USD
    900 STK
    Geldkurs 03.05.24
    3,7800
     
    USD
    300 STK
    Briefkurs 03.05.24
    ISIN: US1710774076 · WKN: A2AG5N · SYM: CDXC · USA

    Neueste Nachrichten

    ChromaDex’s NIAGEN (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar Cellular Nutrition Cellular Energy Supplement
    30.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
    25.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
    24.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market
    23.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Announces Tru Niagen is Now Third-Party Verified Through the Alkemist Assured Transparency Program
    26.03.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
    06.03.24 · Business Wire (engl.) · ChromaDex
    ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
    21.02.24 · Business Wire (engl.) · ChromaDex
    ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
    26.01.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen
    20.12.23 · Business Wire (engl.) · ChromaDex
    A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
    30.11.23 · Business Wire (engl.) · ChromaDex
    Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
    15.11.23 · Business Wire (engl.) · ChromaDex
    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
    09.11.23 · Business Wire (engl.) · ChromaDex